Oncopeptides
Sweden - StockholmBiotechnology
Focus: Oncopeptides is a Swedish biotech company focused on novel cancer treatments, primarily in oncology with a concentrated pipeline in multiple myeloma and related hematologic malignancies. The company is publicly traded and operates at mid-cap biotech scale with a focused therapeutic strategy.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Oncopeptides
AI assessmentNot HiringNo open roles listed right now. Follow Oncopeptides to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Melflufen
Growing
Growth
Lead program in Phase 3 development; core asset driving company value and clinical strategy.
Pipeline & Clinical Trials
Help build intelligence for Oncopeptides
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.